Fibrin-Binding Peptide Modified Heparin for Localized Anticoagulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Patients with cardiovascular disease face complications such as bleeding disorders and thromboembolic issues due to systemic administration of high concentration heparin during and after bypass surgery.
Innovation Solution
Development of a fibrin-binding-peptide modified heparin for localized targeting at the site of treatment, reducing the need for systemic administration and associated risks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high concentration heparin is administered systemically to prevent coagulation in medical devices, then coagulation prevention is achieved, but bleeding disorders and thromboembolic complications occur
Solution Approach 1:
The patent applies local quality by modifying heparin with a fibrin-binding peptide that directs the anticoagulant activity specifically to the graft site where fibrin is present. This localized action prevents coagulation at the target site while minimizing systemic anticoagulation and associated bleeding risks
Solution Approach 2:
The fibrin-binding peptide acts as an intermediary that mediates between the heparin molecule and the fibrin at the graft site. This peptide linker enables targeted delivery of heparin to where it is needed (fibrin-rich areas) without requiring high systemic concentrations
2Reliability
If high concentration heparin is administered systemically to prevent coagulation, then coagulation prevention is achieved, but heparin-associated antibodies develop
Solution Approach 1:
By concentrating heparin activity locally at the graft site through fibrin-binding peptide modification, the systemic exposure to heparin is reduced, thereby decreasing the immunogenic stimulus that leads to heparin-associated antibody formation
3Reliability
If high concentration heparin is administered systemically, then coagulation prevention is achieved, but thromboembolic complications occur
Solution Approach 1:
The targeted delivery of heparin to the graft site creates a localized anticoagulant effect that prevents thrombus formation at the implant site without causing excessive systemic anticoagulation that would lead to thromboembolic complications
4Object-affected harmful factors
If fibrin-binding peptide modified heparin is used for localized targeting, then bleeding risks are reduced, but device compatibility must be maintained
Solution Approach 1:
The invention creates a composite structure by conjugating a fibrin-binding peptide to heparin, combining the anticoagulant properties of heparin with the targeting capability of the peptide. This composite molecule maintains compatibility with existing medical devices while providing enhanced localized activity and reduced bleeding risks
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The technology achieves localized anticoagulation, reducing bleeding risks, enhancing endothelial cell adhesion and proliferation, and improving biocompatibility, while maintaining compatibility with current medical devices.
Implementation Method 1
fibrin-binding peptide covalently linked to the anticoagulant
Data Source
AI summary
Provided herein is technology relating to anticoagulant therapies and particularly, but not exclusively, to anticoagulant compositions for localized and targeted administration and related methods and kits for treatment of a subject with a localized and targeted anticoagulant therapy.